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ABSTRACT
Others have analysed the relationship between inadequate behaviour by healthcare
professionals in the diagnosis of dyslipidaemia (diagnostic inertia) and the history
of cardiovascular risk factors. However, since no study has assessed cardiovascular
risk scores as associated factors, we carried out a study to quantify diagnostic
inertia in dyslipidaemia and to determine if cardiovascular risk scores are associated
with this inertia. In the Valencian Community (Spain), a preventive programme
(cardiovascular, gynaecologic and vaccination) was started in 2003 inviting
persons aged ≥40 years to undergo a health check-up at their health centre. This
cross-sectional study examined persons with no known dyslipidaemia seen during
the first six months of the programme (n = 16,905) but whose total cholesterol
(TC) was ≥5.17 mmol/L. Diagnostic inertia was defined as lack of follow-up to
confirm/discard the dyslipidaemia diagnosis. Other variables included in the analysis
were gender, history of cardiovascular risk factors/cardiovascular disease, counselling
(diet/exercise), body mass index (BMI), age, blood pressure, fasting blood glucose
and lipids. TC was grouped as≥/<6.20 mmol/L. In patients without cardiovascular
disease and<75/≤65 years (n= 15,778/13,597), the REGICOR (REgistre GIronı´ del
COr)/SCORE (Systematic COronary Risk Evaluation) cardiovascular risk functions
were used to classify risk (high/low). Inertia was quantified and the adjusted
odds ratios calculated from multivariate models. In the overall sample, the rate of
diagnostic inertia was 52% (95% CI [51.2–52.7]); associated factors were TC≥ 6.20
mmol/L, high or “not measured” BMI, hypertension, smoking and higher values of
fasting blood glucose, systolic blood pressure and TC. In the REGICOR sample, the
rate of diagnostic inertia was 51.9% (95% CI [51.1–52.7]); associated factors were
REGICOR high and high or “not measured” BMI. In the SCORE sample the rate of
diagnostic inertia was 51.7% (95% CI [50.9–52.5]); associated factors were SCORE
high and high or “not measured” BMI. Diagnostic inertia existed in over half the
patients and was associated with a greater cardiovascular risk.
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INTRODUCTION
Despite the great advances in medicine, coronary heart disease (CHD) and stroke
have remained the main causes of death worldwide for over a decade (WHO, 2014).
Mathematical models based on scoring systems have been used to determine the main risk
factors for these diseases. These factors can be classified as non-modifiable (male gender
and older age) and modifiable (altered lipid levels, diabetes mellitus, high blood pressure
and smoking). These latter factors should be acted on via early detection and control, with
the aim of reducing the incidence of cardiovascular diseases (Wilson et al., 1998; Conroy et
al., 2003; Marrugat et al., 2007; WHO, 2007).
The detection of dyslipidaemia (altered lipid levels in blood) requires obtaining the
blood concentration of lipids (mean of two fasting measurements) and determining
whether that concentration is altered (NCEP & ATP III, 2002). In Spain in 2003, the total
cholesterol (TC) concentration was used to diagnose dyslipidaemia (Villar Alvarez et al.,
2003), with altered values being defined as TC ≥ 5.17 mmol/L (NCEP & ATP III, 2002;
Villar Alvarez et al., 2003). This meant that, if a patient had a TC concentration above this
threshold, the patient should undergo a second measurement to confirm or discard the
diagnosis of dyslipidaemia (NCEP & ATP III, 2002; Villar Alvarez et al., 2003). If, after this
second measurement, the physician then diagnoses dyslipidaemia, he or she should act
according to the relevant guidelines. This action involves various possibilities, including
dietary and hygiene measures or pharmacologic treatment (statins, fibrates and resins)
(NCEP & ATP III, 2002; Villar Alvarez et al., 2003).
In 2010, diagnostic inertia was defined as a derivation of clinical inertia, as defined by
Phillips in 2001 (Phillips et al., 2001; Gil-Guille´n et al., 2010). Diagnostic inertia was defined
as a situation in which a patient fulfilled the diagnostic criteria for a particular disorder
but was not diagnosed by the respective physician as having this disorder (Gil-Guille´n et
al., 2010). A paper published in 2014 examined this concept in dyslipidaemia, considering
the concentrations of TC and high-density lipoprotein cholesterol (HDL-C). This paper
also undertook an exhaustive literature search detailing the main characteristics of
those studies that had assessed failures in the diagnosis of dyslipidaemia, even though
these studies had not in fact used the term diagnostic inertia to refer to these failures
(Palazo´n-Bru et al., 2014).
Some of these authors evaluated the history of cardiovascular risk factors (CVRF)
in relation to diagnostic inertia (Palazo´n-Bru et al., 2014), but none of them assessed
the cardiovascular risk using a scoring system obtained through a multivariate model,
considering the current status of the patients (current situation regarding CVRF;
for example, current TC or HDL-C levels), rather than the already diagnosed CVRF.
Therefore, we conducted a study calculating the cardiovascular risk in the patients using
the following scoring systems: REGICOR (REgistre GIronı´ del COr) (calibration for
Spanish persons of one of the scales of the Framingham study to evaluate morbidity and
mortality due to coronary disease) and SCORE (Systematic COronary Risk Evaluation)
(cardiovascular risk function in Europe, version TC/HDL-C) (Wilson et al., 1998; Conroy et
al., 2003; Marrugat et al., 2007). We then examined the association of these cardiovascular
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risk scores in relation to the behaviour of the healthcare professionals. This type of
association was examined by Sepehri et al. (2014) in their analysis of lack of advice to
obese patients about losing weight. However, we have been unable to find any studies
that analysed the situation as we proposed to do in this study. Accordingly, the results are
innovative and highlight the need for measures to improve the diagnosis of dyslipidaemia.
MATERIALS & METHODS
Setting
The Valencian Community (Spain) had 4,518,126 inhabitants in 2004 (Instituto Nacional
de Estadı´stica, 2004). Primary healthcare is provided at health centres; coverage is universal
and there is no cost to the patient. In this Community, a preventive activities programme
following the recommendations of the Spanish guidelines was started at the end of 2003,
aimed at the whole population aged 40 years or over (Pareja Bezares et al., 1999; Villar
Alvarez et al., 2003; Robledo de Dios et al., 2003; Del Cura Gonza´lez, Arribas Mir & Coutado,
2003). Each person was invited, first by normal mail and then by telephone, to attend their
health centre for a preventive study by medical and nursing personnel. The participants
were given a report with the result of the examination and opportune recommendations,
a copy of which was kept at the health centre. This programme included cardiovascular
and gynaecologic screening and a vaccination campaign. The healthcare professionals who
participated in this programme were dedicated solely to this job.
Study population
The study comprised all the patients who attended their health centres for the preventive
activities programme. The main characteristics of these persons were: high prevalence of
CVRF, older age, mostly women, and frequent attenders (Pedrera Carbonell et al., 2005).
Study design and participants
This was a cross-sectional study that analysed a sample of all individuals without known
dyslipidaemia who were ≥40 years and who participated during the first six months in
the preventive activities programme of the Valencian Community but who had an altered
screening for TC (TC≥ 5.17 mmol/L) (NCEP & ATP III, 2002; Villar Alvarez et al., 2003).
Dyslipidaemia was defined according to the ICD-9-CM (272.x). Any patient who failed to
fulfil these requirements was excluded from this study.
Variables and measurements
For this study we included all the cardiovascular data measured during the programme.
Diagnostic inertia was the primary outcome variable. A patient was considered to
experience diagnostic inertia if the healthcare professional failed to interpret correctly an
altered TC screening result; that is the professional failed to start a follow-up programme of
the patient to confirm or discard a diagnosis of dyslipidaemia.
The following secondary variables were considered: gender; personal history of diseases
(hypertension, diabetes, CHD and stroke), personal history of smoking, counselling about
diet and exercise (Yes or No), body mass index (BMI) (in kg/m2), age (in years), systolic
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and diastolic blood pressure (in mmHg), fasting blood glucose (FBG) (in mmol/L) and
lipid profile (TC and HDL-C, in mmol/L).
The BMI, FBG, blood pressure and lipid profile were obtained using the standard
methods. In some patients the BMI was not determined, in which case it was recorded
as “not measured.” Data concerning the personal history of diseases, the smoking habit,
the gender and the age were obtained at the patient interview and corroborated from the
charts. Any counselling was recorded in the clinical history.
After obtaining all the data, the variables were grouped as follows (WHO, 1997): (1)
BMI: “not measured”, low or normal (BMI < 25 kg/m2), overweight (BMI ≥ 25 kg/m2
and BMI< 30 kg/m2) and obese (BMI≥ 30 kg/m2); (2) personal history of cardiovascular
disease (CVD): having had CHD or stroke; and (3) TC values: TC ≥ 6.2 mmol/L and
TC< 6.2 mmol/L (NCEP & ATP III, 2002; Villar Alvarez et al., 2003).
For each patient all the parameters in the preventive programme were recorded during
one morning (systolic and diastolic blood pressure, FBG, BMI, TC and HDL-C). After
collection, and on the same morning as the collection, the physician met the relevant
patient and determined whether a future visit should or should not be arranged to confirm
or discard a diagnosis of dyslipidaemia. In addition, at the same time the patient could
receive personalized advice about exercise or diet.
After the collection and digitalization of the data and grouping the variables, the
REGICOR cardiovascular risk function was ascertained in those patients for whom it
was applicable. These patients were then classified in risk groups: high (≥20%) and low
(<20%). The REGICOR scale estimates the 10-year probability of CHD in patients free of
CVD between the ages of 30 and 74 years (Marrugat et al., 2007). CVD predictive variables:
gender, age, lipid profile (TC and HDL-C), systolic and diastolic blood pressure, diabetes
and smoking.
The same procedure was followed in those patients for whom the SCORE was applicable
(version TC/HDL-C). The risk groups were (Conroy et al., 2003): high (≥5%) and low
(<5%). The SCORE estimates the 10-year risk of cardiovascular death in patients aged
40–65 years with no previous CVD. The variables in this model are: age, gender, TC,
HDL-C, systolic blood pressure, and smoking.
Sample size
The overall sample comprised 16,905 patients with no personal history of dyslipidaemia
and with TC≥ 5.17 mmol/L. Of these, 15,778 fulfilled the criteria for REGICOR evaluation
and 13,597 for SCORE. Thus, using a significance of 5% and a maximum expected
proportion (p = q = 50%), the expected error in the estimation of the proportion of
diagnostic inertia was 0.75% in the overall sample, 0.78% in the REGICOR patients, and
0.84% in the SCORE patients.
Statistical analysis
The descriptive analysis was performed using the standard methodology in health sciences
(frequencies, percentages, means and standard deviations). Multivariate logistic regression
models were used to estimate the adjusted odds ratio (OR) in order to analyse the
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association between diagnostic inertia and the study variables. For the overall sample,
the ORs were adjusted for gender; personal history of diseases and smoking, BMI group,
counselling, TC group, and age as a quantitative variable. Another model was performed
with the total sample using the current status of the CVRF (systolic blood pressure, TC and
FBG), instead of the personal history of hypertension or diabetes mellitus, and TC≥ 6.20
mmol/L. For the REGICOR sample, the ORs were adjusted for REGICOR risk group, BMI
group, and counselling. For the SCORE sample, the ORs were adjusted for SCORE risk
group, personal history of diabetes, BMI group, and counselling. The rest of the variables
in all the models were not taken into account due to collinearity issues. The prognostic
probabilities of inertia were also studied in multivariate models to produce charts in
order to aid interpretation of the results. The goodness-of-fit of the models was tested
by the likelihood ratio test. Furthermore, the unadjusted ORs were calculated for all the
secondary variables. All the analyses were done with a level of significance of 5%, and the
associated confidence interval (CI) of each parameter was calculated. All the analyses were
done with IBM SPSS Statistics 19.
Ethical considerations
This study was approved by the Conselleria de Sanitat-Miguel Herna´ndez University insti-
tutional review committee (Valencian Community) with reference number AVS-UV1.07X.
This institution did not participate in data collection, analysis or interpretation, or in the
decision to approve or disapprove publication of the final manuscript. In addition, the data
were anonymized and encrypted, satisfying the data protection law.
As our study was population-based and non-interventional, using data from medical
records, no informed consent was required. The institutional review committee approved
this procedure and ensured that information access was completely restricted. In addition,
its use was in line with current legislation.
RESULTS
Total sample
Table 1 summarizes the information concerning the overall sample (n = 16,905). Most of
those who participated in the study were women (60.6%), there was a high prevalence of
CVRF (hypertension, 17.3%; diabetes, 3.5%; smoking, 22.1%), almost 4% of CVD, and the
vast majority of the patients had TC concentrations below 6.20 mmol/L (69.5%). Table 1
also shows the unadjusted ORs for all the secondary variables.
The magnitude of inertia was 52.0% (95% CI [51.2–52.7]). Significantly associated
factors (p < 0.05) in the multivariate models were: hypertension, smoking, higher BMI
(overweight and obesity) or “not measured” BMI, TC≥ 6.2 mmol/L and higher values of
the control parameters of the CVRF (systolic blood pressure, FBG and TC). These results
were similar to the unadjusted ORs (Table 1).
REGICOR sample
In the REGICOR sample (n = 15,778), the proportion of inertia was 51.9% (95%
CI [51.1–52.7]). Significantly associated factors were: a high REGICOR (≥20%)
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Table 1 Analysis of diagnostic inertia for dyslipidaemia at primary health care centres in the Valencian Community (Spain): 2003–2004
data. ORs were adjusted for gender; personal history of hypertension, diabetes, smoking and CVD; BMI groups, counselling (diet and exercise),
total cholesterol values (as a categorical variable) and age. Systolic and diastolic blood pressure, total and HDL cholesterol were not included in the
multivariate model due to collinearity with the personal history of hypertension and TC ≥ 6.2 mmol/L. A second model was performed (current
status of the cardiovascular risk factors) replacing TC ≥ 6.20 mmol/L, personal history of hypertension and diabetes by TC (in mmol/L), systolic
blood pressure and fasting blood pressure. In this last model, diastolic blood pressure and HDL cholesterol were not included due to collinearity
with systolic blood pressure and TC. Goodness-of-fit of the models: (1) Personal history of cardiovascular risk factors: X2 = 4,750.1 P < 0.001; (2)
Current status of the cardiovascular risk factors: X2 = 4,834.1 P < 0.001.
Variable Total Inertia Unadj. OR P Adj. OR P
16,905 8,783 (52.0%) (95% CI) (95% CI)
n(%)/x±s n(%)/x±sd
Age (Years) 54.7±9.9 54.8±9.9 1.00(1.00, 1.01) 0.12 1.00(0.99, 1.00) 0.13
REGICOR (probability of event)b 5.8±3.6 6.5±4.0 1.12(1.11, 1.14) <0.001 N/M N/M
REGICOR risk groups:
≥20% 128(0.8) 112(87.5) 6.57(3.89, 11.10) <0.001 N/M N/M
<20%a,b 15,650(99.2) 8,074(51.6)
SCORE (probability of event)b 1.3±1.9 1.6±2.3 1.22(1.19, 1.25) <0.001 N/M N/M
SCORE risk groups:
≥5% 551(4.1) 414(75.1) 2.94(2.41, 3.57) <0.001 N/M N/M
<5%a,b 13,046(95.9) 6,616(50.7)
Gender:
Male 6,664(39.4) 3,679(55.2) 1.24(1.17, 1.32) <0.001 0.97(0.91, 1.05) 0.49
Femalea 10,241(60.6) 5,104(49.8)
Personal history of hypertension:
Yes 2,923(17.3) 2,087(71.4) 2.72(2.49, 2.96) <0.001 4.27(3.85, 4.73) <0.001
Noa 13,982(82.7) 6,696(47.9)
Personal history of diabetes:
Yes 592(3.5) 351(59.3) 1.36(1.15, 1.61) <0.001 1.16(0.96, 1.41) 0.13
Noa 16,313(96.5) 8,432(51.7)
Personal history of smoking:
Yes 3,739(22.1) 2,779(74.3) 3.45(3.18, 3.74) <0.001 4.94(4.50, 5.42) <0.001
Noa 13,166(77.9) 6,004(45.6)
Personal history of CVD:
Yes 639(3.8) 341(53.4) 1.06(0.91, 1.24) 0.47 0.86(0.71, 1.03) 0.10
Noa 16,266(96.2) 8,442(51.9)
BMI groups (kg/m2):
<25a 4,157(24.6) 2,038(49.0)
25–30 7,355(43.5) 3,803(51.7) 1.11(1.03, 1.20) 0.01 1.08(0.99, 1.18) 0.09
≥30 4,357(25.8) 2,360(54.2) 1.23(1.13, 1.34) <0.001 1.10(1.00, 1.22) 0.06
Not measured 1,036(6.1) 582(56.2) 1.33(1.16, 1.53) <0.001 1.26(1.07, 1.48) 0.01
Diet counselling:
Yes 14,407(85.2) 7,542(52.3) 1.11(1.02, 1.21) 0.02 1.02(0.91, 1.15) 0.72
Noa 2,498(14.8) 1,241(49.7)
Exercise counselling:
Yes 14,369(85.0) 7,476(52.0) 1.02(0.93, 1.11) 0.71 0.99(0.88, 1.12) 0.86
Noa 2,536(15.0) 1,307(51.5)
(continued on next page)
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Table 1 (continued)
Variable Total Inertia Unadj. OR P Adj. OR P
16,905 8,783 (52.0%) (95% CI) (95% CI)
n(%)/x±s n(%)/x±sd
Total cholesterol values (mmol/L):
≥6.2 5,158(30.5) 4,189(81.2) 6.73(6.22, 7.29) <0.001 8.33(7.63, 9.09) <0.001
<6.2a 11,747(69.5) 4,594(39.1)
Systolic blood pressure (mmHg)c 128.9±17.3 130.5±17.9 1.01(1.01, 1.01) <0.001 1.01(1.01, 1.01) <0.001
Diastolic blood pressure (mmHg) 78.4±10.4 79.2±10.7 1.02(1.01, 1.02) <0.001 N/M N/M
Total cholesterol (mmol/L)c 6.0±0.7 6.2±0.8 5.90(5.50, 6.32) <0.001 6.58(6.10, 7.09) <0.001
HDL cholesterol (mmol/L) 1.5±1.2 1.7±1.1 0.98(0.94, 1.02) 0.41 N/M N/M
Fasting blood glucose (mmol/L)c 5.5±1.4 5.5±1.4 1.09(1.06, 1.11) <0.001 1.05(1.02, 1.08) <0.001
Notes.
Abbreviations: Adj. OR, adjusted odds ratio; Unadj. OR, unadjusted odds ratio; CI, confidence interval; REGICOR, REgistre GIronı´ del COr; SCORE, Systematic
COronary Risk Evaluation; HDL, high density lipoprotein; CVD, cardiovascular disease; BMI, body mass index; N/M, not in the models.
a Reference.
b Only when the scoring system was applicable.
c Adjusted with the current status of the cardiovascular risk factors (systolic blood pressure, total cholesterol and fasting blood glucose).
d Prevalence of inertia.
(OR = 6.49, 95% CI [3.84–10.98], p < 0.001), obesity or “not measured” BMI (BMI
< 25 kg/m2 →OR= 1; BMI 25–29.9 kg/m2 →OR= 1.11, 95% CI [1.03–1.20], p= 0.08;
BMI≥ 30 kg/m2 → OR = 1.21, 95% CI [1.11–1.33], p < 0.001; BMI “not measured”→
OR= 1.32, 95% CI [1.15–1.52], p < 0.001), and counselling about diet (OR= 1.13, 95%
CI [1.01–1.25], p= 0.03).
Figure 1A shows a Cartesian chart of the risk groups according to the REGICOR on the
X axis and prognostic probability of inertia on the Y axis. The chart shows that persons
with a high risk had a greater probability of inertia.
SCORE sample
In the analysis done for the SCORE sample (n = 13,597) the proportion of inertia
was 51.7% (95% CI [50.9–52.5]). Significantly associated factors were: a high SCORE
(≥5%) (OR = 2.85, 95% CI [2.34–3.47], p < 0.001), diabetes (OR = 1.27, 95% CI
[1.02–1.59]; p = 0.04), a higher BMI (overweight and obesity) or “not measured” BMI
(BMI < 25 kg/m2 → OR = 1; BMI 25–29.9 kg/m2 → OR = 1.13, 95% CI [1.04–1.23],
p = 0.01; BMI ≥ 30 kg/m2 → OR = 1.19, 95% CI [1.08–1.31], p < 0.001; BMI “not
measured”→OR= 1.31, 95% CI [1.12–1.53], p < 0.001), and counselling about diet (OR
= 1.15, 95% CI [1.03–1.29], p= 0.01).
Fig. 1B shows a Cartesian chart of the risk groups according to the SCORE on the X axis
and prognostic probability of inertia on the Y axis. The chart shows that persons with a
greater cardiovascular risk experienced more inertia.
DISCUSSION
This study shows that a greater cardiovascular risk is related to experiencing diagnostic
inertia when the physician fails in the interpretation of altered TC levels in patients who
have no personal history of dyslipidaemia. This greater cardiovascular risk thus leads to an
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Figure 1 Predicted probability of diagnostic inertia for dyslipidaemia for primary cardiovascular
prevention patients. Abbreviations: REGICOR, REgistre GIronı´ del COr; SCORE, Systematic COronary
Risk Evaluation.
association between cardiovascular risk factors and diagnostic inertia. These risk factors
were hypertension, higher systolic blood pressure, smoking, a high BMI (overweight
and obesity) or “not-measured” BMI, higher TC concentrations, a high probability of
developing a lethal or nonlethal CVD, a personal history of diabetes and higher values of
FBG. In addition, dietary advice was also associated with diagnostic inertia.
Most previous studies differ from ours in these associations (Palazo´n-Bru et al., 2014),
as only one paper found an association between the presence of cardiovascular risk factors
and lack of a correct diagnosis of dyslipidaemia when there existed alterations in the levels
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of HDL-C (Palazo´n-Bru et al., 2014). On the other hand, the study by Sepehri et al. (2014)
did, however, find an association between having a high REGICOR and experiencing
clinical inertia for the treatment of obesity by personalized counselling to lose weight.
These results are of concern, as these patients have a very high likelihood of suffering
CVD if no preventive measures are taken. Controlling blood pressure, the lipid profile,
body weight, diabetes and ceasing to smoke are the main measures. Also of note was the
greater inertia in persons offered personalized advice about adequate nutrition. This may
be because healthcare professionals (physicians and nurses) prefer to give dietary advice
rather than measure the TC, because the concentration of TC will decrease if the patient
follows this advice. Furthermore, these results were seen during a cardiovascular preventive
activities programme, in which the healthcare professionals had to either confirm or
discard the diagnosis of dyslipidaemia. We found that half of the patients did not undergo
a second measurement of TC, even though many were diagnosed with other CVRF and
they should have had their lipid profile controlled to avoid CVD. This may be because
most of these patients had multiple disorders and were polymedicated (Pedrera Carbonell
et al., 2005), so that the healthcare professional decided not to order a dyslipidaemia
confirmatory test at that time, as this would only increase the therapeutic complexity
of the patient. Finally, a factor that we thought might have influenced the decision to
monitor the patient was that the healthcare professional would accept borderline TC
figures (TC < 6.20 mmol/L) as normal (NCEP & ATP III, 2002; Villar Alvarez et al.,
2003). Our results, though, unexpectedly showed that greater inertia was committed in
persons with non-borderline TC figures. Given that the aim of the study was restricted to
determining factors associated with this inertia, a qualitative study should be undertaken
to attempt to determine the reasons why the healthcare professionals fail to adhere to
the clinical practice guidelines when diagnosing dyslipidaemia. This would enable us to
corroborate the theories put forward (dietary advice instead of a second drug; patients with
multiple diseases or on multiple drugs for whom the professional does not wish to increase
the therapeutic complexity) and thus provide further understanding that would aid the
healthcare professional when diagnosing dyslipidaemia, and which would hopefully result
in an earlier diagnosis of the disorder.
The results of this study suggest the need to design measures aimed at reducing this
diagnostic inertia. Worryingly, this diagnostic inertia was associated with a greater
cardiovascular risk, both when assessed from a history of CVRF (or using the values of
the control parameters) and when using a scoring system. A possible solution to this
problem might be the inclusion of training courses in the health centres to remind the
healthcare providers of the cut points for the diagnosis of the various CVRF. In addition,
as suggested by others (Palazo´n-Bru et al., 2014; Sepehri et al., 2014), in order to reduce
inertia it might be beneficial to integrate some sort of alarm in the computerized electronic
records systems in the event that a TC measurement is abnormal. This would help the
healthcare professional see that a diagnosis of dyslipidaemia should be confirmed in a
patient who has an altered screening for TC. The end result of this could be a reduction in
the incidence of CHD.
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Limitations and strengths of the study
The main strength of this study is that it is the first to examine the association between
diagnostic inertia in dyslipidaemia and the cardiovascular risk, as measured with
probabilistic functions (REGICOR and SCORE). The results are therefore innovative.
In addition, the large sample size and the participation of all the primary care physicians
and nurses in the Valencian Community provide external validity to our conclusions.
Concerning selection bias, it should be recalled that we are evaluating data from a
cardiovascular preventive programme, in which all the healthcare professionals had been
instructed to undertake cardiovascular preventive activities with all their patients. This
begs the reflection about what the situation would actually be in daily clinical practice;
i.e., when the healthcare professionals follow their own criteria for ordering screening tests
for the diagnosis of dyslipidaemia. This remains to be examined in future studies, which
will then enable comparison with the present results. Another limitation concerns the fact
that we were unable to include certain variables that could affect the outcome, such as
psychosocial factors of both the healthcare professionals and the patients. This remains for
future studies, once the above-mentioned qualitative study has been undertaken and the
results analysed.
As regards measurement bias, the teams taking the measurements were requested to
use reliable devices and to undertake the clinical interview correctly. Nevertheless, only
TC was assessed as a lipid parameter to diagnose dyslipidaemia. The reason for not using
low-density lipoprotein cholesterol, HDL-C or triglycerides is because in the year the
preventive programme was carried out the Spanish clinical guidelines only advised the
use of this parameter (Villar Alvarez et al., 2003). Finally, even though the data are from
2003–2004, we should nevertheless consider that the problem of diagnostic inertia (though
it was not yet referred to as such) has been the subject of study since the 1980s. Even
nowadays it still exists, despite newer guidelines and changes in the diagnostic cut points
(Palazo´n-Bru et al., 2014). In other words, the results of this study, whilst not very recent,
can still indicate the need for diagnostic inertia to be considered at the current time.
CONCLUSIONS
Diagnostic inertia occurred in over half the patients with no personal history of
dyslipidaemia but who had an altered screening test and who attended a preventive
activities programme. Worryingly, the healthcare professionals committed greater inertia
in the patients who had a higher likelihood of CVD.
Given the relevance of the problem found, measures are needed to reduce the magnitude
of inertia, particularly in the case of patients with a high cardiovascular risk.
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